Application of the metabolic inhibitor 2-Deoxy-D-Glucose to treat autoimmune disease in mice.

Rachel Burke

Document Type

Article

Publication Date

Summer 2016

JAX Location

In: Student Reports, Summer 2016, Jackson Laboratory

Abstract

Recent work with mouse models of systemic lupus erythematosus (SLE), Foxp3 scurfy, and SJL B-cell lymphomas has demonstrated the potential of the classic glycolysis inhibitor 2-Deoxy-D-Glucose (2DG) as a drug with broad application to treatment of autoimmune disease. This study sought to extend previous research on 2DG treatments in two mouse models: the BXSB.Yaa model for SLE and K/BxN model for rheumatoid arthritis (RA). In response to concerns of 2DG toxicity in other animal models, this study examined the efficacy of 1.5g 2DG/500mL and 0.6g 2DG/500mL (mass drug per volume acidified drinking water) in BXSB.Yaa-IL21VFP mice, to determine whether lower doses than the originally-tested 3g/500mL can significantly attenuate the autoimmune response. To assess the potential of 2DG in RA, K/BxN mice were administered a dose of 3g/500mL to determine whether the drug can inhibit the development of arthritis. The goal of this study was to expand knowledge regarding 2DG and autoimmune disease, with the hope that the findings can inform future research on the applicability of 2DG as an effective, lower-cost treatment for human autoimmune disorders

Please contact the Joan Staats Library for information regarding this document.

COinS